Orvida distributes medical-grade aesthetic products across Portugal and Spain. We believe patient safety and environmental responsibility should advance together — quietly, measurably, and without compromise to clinical integrity.
We distribute CE 2460, ISO 13485 products for injection into human tissue. That reality shapes every environmental decision we make. Here is how we reconcile the two.
Sustainability never compromises cold chain, sterility, or traceability. Every switch we make — packaging, carrier, handling — is validated against MDR and ISO 13485 controls before adoption.
Transitioning to FSC-certified outer cartons, recyclable cold-chain packs, and returnable thermal inserts for volume clinics. Less waste at the treatment room, less landfill at its end.
Iberia-focused distribution from a single EU hub. Direct air-to-cold-chain handover reduces transfer legs between manufacturer and clinic door. Fewer hands, fewer miles, fewer emissions.
Manufacturer audited to ISO 13485 with non-animal-origin hyaluronic acid (biofermentation). No animal testing, in line with EU Cosmetics Regulation and MDR requirements.
We prefer dated commitments over round-number pledges. Below is where each workstream stands today, with status marked plainly. We update this list each quarter.
Our manufacturing partner, Hangzhou Techderm Biological Products Co., Ltd., operates under ISO 13485 and ISO 9001, with export clearance to sixty-plus regulated markets. We audit production controls annually and the facility is subject to EU MDR 2017/745 notified-body oversight under CE 2460.
Every hyaluronic acid batch is biofermented, non-animal in origin. There is no animal testing at any stage of R&D or release. This is non-negotiable — it is also the only way a modern aesthetic filler should be made.
Each unit arrives with a QR authentication code, linked to lot number, manufacture date, and chain of custody. A clinic can verify authenticity at the treatment room before a single syringe is opened.
Shorter is honest. We would rather commit to what we can measure over thirty-six months than publish a 2050 pledge that outlives the team that wrote it.
Clinics, suppliers, and industry peers working on lower-impact aesthetic medicine — we are open to conversation. Share what you are doing, and we will share ours.